Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune‐mediated thrombotic thrombocytopenic purpura-Reference-Cited by-同舟云学术

Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune‐mediated thrombotic thrombocytopenic purpura

Published:2019-03-28 Issue:5 Volume:185 Page:912-917
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Stubbs Matthew J.¹^ORCID,Low Ryan¹,McGuckin Siobhan¹,Newton Rosalind¹,Thomas Mari¹²,Westwood John P.¹,Shah Raakhee¹,Cheesman Simon¹,Scully Marie A.¹²^ORCID

Affiliation:

1. Department of Haematology UCLH NHS Foundation Trust London UK

2. Department of Haematology UCLH and Cardiometabolic Programme‐NIHR UCLH/UC BRC London London UK

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15874

Reference16 articles.

1. Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey

2. The US Approach to Biosimilars

3. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10

4. Perspectives on the Current State of the Biosimilar Regulatory Pathway in the United States

5. EMA. (2012)Guideline on similar biological medicinal products containing monoclonal antibodies – non‐clinical and clinical issues. EMA/CHMP/BMWP/403543/2010. European Medicines Agency London UK.https://www.ema.europa.eu/documents/scientific-guideline/guidelinesimilar-biological-medicinal-products-containing-monoclonal-antibodies-nonclinical_en.pdf

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors of relapse and prophylactic management of immune thrombotic thrombocytopenic purpura;Transfusion and Apheresis Science;2023-08

2. Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience;Internal and Emergency Medicine;2023-02-24

3. Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy;Blood;2023-01-19

4. Advances in the management of TTP;Blood Reviews;2022-09

5. A Developer’s Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10;Clinical Drug Investigation;2022-03-24